Reference : Tryptophan catabolism increases in breast cancer patients compared to healthy control...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/240021
Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
English
ONESTI, Concetta Elisa mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale >]
BOEMER, François mailto [Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire Biochimie Génétique >]
JOSSE, Claire mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale >]
LEDUC, Stéphane mailto [Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire Biochimie Génétique >]
BOURS, Vincent mailto [Centre Hospitalier Universitaire de Liège - CHU > Unilab > Service de génétique >]
JERUSALEM, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale >]
2019
Journal of Translational Medicine
BioMed Central
17
239
Yes (verified by ORBi)
International
1479-5876
United Kingdom
[en] Background: Indoleamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenine, an immunosuppressive metabolite involved in T regulatory cell differentiation. Indoleamine 2,3-dioxygenase is expressed in many cancer types, including breast cancer. Here, we analyze kynurenine and tryptophan and their ratio in breast cancer patients and healthy controls. Methods: Breast cancer patients and healthy controls were prospectively enrolled in our study. All subjects underwent blood sample withdrawal at diagnosis or on the day of screening mammography for the healthy controls. Plasmatic kynurenine and tryptophan were determined on a TQ5500 tandem mass spectrometer after chromatographic separation. Results: We enrolled 146 healthy controls and 202 women with stages I–III breast cancer of all subtypes. All patients underwent surgery, 126 underwent neoadjuvant chemotherapy with 43 showing a pathological complete response, and 43 underwent adjuvant chemotherapy. We observed significantly higher plasmatic kynurenine, tryptophan and their ratio for the healthy controls compared to patients with breast cancer. We observed a lower plasmatic tryptophan and a higher kynurenine/tryptophan ratio in hormone receptor-negative patients compared to hormone receptor-positive cancers. Lobular cancers showed a lower ratio than any other histologies. Advanced cancers were associated with a lower tryptophan level and higher grades with an increased kynurenine/tryptophan ratio. Pathological complete response was associated with higher kynurenine values. The plasmatic kynurenine, tryptophan and kynurenine/tryptophan ratios were not predictive of survival. Conclusions: The plasmatic kynurenine, tryptophan and kynurenine/tryptophan ratio could differentiate breast cancer patients from healthy controls. The Kyn/Trp ratio and Trp also showed different values according to hormone receptor status, TNM stage, T grade and histology. These results suggest a rapid metabolism in breast cancer, but no associations with outcome or sensitivity to chemotherapy were observed.
http://hdl.handle.net/2268/240021
10.1186/s12967-019-1984-2

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Trp Kyn.pdfPublisher postprint1.34 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.